SEOTEMBER 10, 2024
What’s Happening in Healthcare: Q4 2024
GLP-1s, Employers, and the role of utilization
IRA price cuts become clear
Manufacturer
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson
Bristol Myers
Eli Lilly
Merck
Amgen
AstraZeneca
Novo Nordisk
Novartis
Drug
Xarelto
Imbruvica
Stelara
Eliquis
Jardiance
Januvia
Enbrel
Farxiga
Fiasp
Entresto
Primary Use
Anticoagulant
Blood cancer treatment
Infusion immunosuppressive drug
Anticoagulant
Type 2 diabetes treatment
Type 2 diabetes treatment
Autoinjector, arthritis, plaque psoriasis
Type 2 diabetes, heart failure risk reduction
Insulin injectable
Heart failure risk reduction
2023 Price
$517
$14,934
$13,836
$521
$573
$527
$7,106
$556
$495
$628
2026 Price
(Post-negotiation)
$197
$9,139
$4,695
$231
$197
$113
$2,355
$178
$119
$295
Percent
Reduction
62%
38%
66%
56%
66%
79%
67%
68%
76%
53%
Source: fiercepharma.com
It’s time to put these phrases to bed
Workforce crisis
Bandwidth
Providers
Burnout
Population health
Value-based care
Sandoz
Alvotech
Amgen
Fresnius
40%
Infusion Centers Are Opening Across the Country
Learn More
Founded in 2018, VistaRx (Vista) provides comprehensive pharmacy data capture and management solutions for a variety of entities in the pharmacy value chain. We utilize custom-coded technology, strategies, and partnerships to help our clients improve operations and reduce dependence on third-party vendors.